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EDITORIAL REVIEW
The biological action of calcitriol in renal failure
Abnormal calcitriol [1,25(OH)2 vitamin D] metabolism plays a
major role in the pathophysiology of renal osteodystrophy and
other alterations of mineral metabolism associated with chronic
renal failure. Growing knowledge of the protean biologic actions
of calcitriol suggests that abnormal calcitriol metabolism may also
play a role in other homeostatic perturbations associated with
renal failure such as abnormal immune function [1—5], impaired
growth and development [61, and abnormal cardiac [71 and
skeletal muscle [8, 9] function. In view of the central and enlarging
role of calcitriol in the pathophysiology of the uremic syndrome,
it is important to understand the nature of altered calcitriol
metabolism in renal failure. Emerging evidence has focused on
three primary areas of altered calcitriol metabolism in renal
failure: diminished production of calcitriol, decreased concentra-
tion of the calcitriol receptor, and altered DNA binding proper-
ties of the receptor-hormone complex. These alterations result in
attenuated end-organ responsiveness to calcitriol and the conse-
quent abnormalities of mineral metabolism and other functions
[10—14]. The nature of the alterations in calcitriol metabolism are
reviewed in detail in this report with an emphasis on the recently
appreciated contributory role of uremic toxins.
Calcitriol production in renal failure
Extracellular concentration of calcitriol is decreased in patients
with chronic renal failure [15] and in the renal ablation model of
renal failure [16]. Several studies suggest that the plasma calcitriol
concentration may be perceptibly decreased in the early phases of
renal failure [17, 18]. The fall in serum calcitriol concentration in
renal failure is mainly attributable to decreased renal production
of calcitriol. A number of factors contribute to the fall in renal
production including loss of renal mass [16], phosphate retention
[19], and metabolic acidosis [20].
Decreased renal mass has long been considered to be a major
factor responsible for the decreased total production rate and
serum concentration of calcitriol in chronic renal failure. Ordi-
narily, the proximal tubular cell of the kidney is the site of
conversion of 25(OH)D3 to the much more biologically active
calcitriol [21]. Prince et al [22] have shown that calcitriol produc-
tion can be stimulated in patients with mild renal failure, suggest-
ing that factors other than decreased renal mass account for
decreased production. Hyperphosphatemia is a universal finding
in moderate to advanced renal failure owing to decreased filtra-
tion of serum phosphorus as the glomerular filtration rate falls.
Phosphorus suppresses calcitriol production by the kidney [23],
whereas dietary phosphorus restriction increases plasma concen-
tration of calcitriol in normal [24] and renal failure subjects [191.
Received for publication August 2, 1993
and in revised form October 22, 1993
Accepted for publication October 25, 1993
© 1994 by the International Society of Nephrology
Metabolic acidosis occurs frequently with chronic renal failure
and has been shown to suppress calcitriol production [25]. How-
ever, the issue remains controversial because other studies have
not found that chronic acidosis decreases plasma calcitriol [26,
27}. Recent studies suggest that acidosis suppresses la-hydroxy-
lase activity indirectly by increasing the ionized calcium concen-
tration in serum [28,29] and in proximal tubule mitochondria [30].
In addition to the factors described above, several lines of
evidence from our laboratory indicate a potentially important role
for uremic toxins in the suppression of calcitriol synthesis. For
example, there is an additional fall in calcitriol production when
partially nephrectomized rats are placed on a high protein diet
[31]. We have proposed that a high protein diet increases the
generation of uremic toxins which further suppress calcitriol
production beyond what occurs with renal failure alone. Further-
more, when urine, from which phosphorus had been removed, was
infused into normal rats, there was a decrease in calcitriol
production [31]. Infusion of uremic plasma ultrafiltrate to normal
rats in an amount that did not raise plasma concentrations of urea
nitrogen or creatinine also suppressed the calcitriol production
rate and renal lcx-hydroxylase activity. Enzyme activity was also
inhibited in kidney homogenates incubated with uremic ultrafil-
trate (Fig. 1) [32]. The ultrafiltration process excludes substances
with a molecular weight greater than 10,000, indicating that small
molecular weight substances present in normal urine and plasma
of patients with renal failure are capable of suppressing calcitriol
production independent of any reduction in functional renal mass.
In an effort to better characterize the toxins, plasma ultrafil-
trates of normal subjects and hemodialysis patients were divided
by semi-preparative high performance liquid chromatography
(HPLC) into 13 distinct fractions. We found at least two groups of
chemically distinguishable compounds that profoundly inhibited
calcitriol production [33]. One inhibition region localized to
fractions 6 to 13. Several chemical substances co-eluted in these
fractions including hippuric acid, indole-3-acetic acid, tryptophan,
and indoxyl sulfate [33]. None of these compounds have been
tested for their effects on calcitriol production. The other region
of inhibition was eluted in fraction 4 which co-eluted with the
purine compounds: uric acid, xanthine, hypoxanthine, and gua-
nidinosuccinic acid (GSA).
We studied the effect of purines and related substances (such
as, uric acid, xanthine, and theophylline) on the production rate of
calcitriol in normal rats. Infusion of uric acid for 20 hours into
normal rats at a rate sufficient to raise the plasma urate concen-
tration from 1.1 to 4.2 mg/dl resulted in a 42% reduction in the
calcitriol production rate and suppression of renal la-hydroxylase
activity [34]. Similarly, calcitriol production by kidney homoge-
nate was reduced by incubating with xanthine for three hours [34].
The effect of uric acid on plasma concentration of calcitriol was
further investigated in nine patients with stable chronic renal
failure. Plasma calcitriol levels were measured before and one
week after administration of allopurinol, 300 mg daily. The
606 Hsu et al: Calcitriol in renal failure
100
80
*(Q)
60
*
40 *
02jj4
30
plasma uric acid concentration decreased (7.3 0.4 mg/dl to 4.0
0.4 mg/dl, N = 9, P < 0.01) and the calcitriol concentration
increased in each patient after ingestion of allopurinol (plasma
calcitriol, 30.8 2.7 to 38.2 4.8 pg/mi, P < 0.01) [35].
Allopurinol itself, tested in normal rats, has no effect on renal
la-hydroxylase and calcitriol synthesis. Theophylline, a purine
related compound, also markedly inhibited lcs-hydroxylase activ-
ity and calcitriol synthesis in normal rats [34]. Thus, uric acid and
related related compounds appear to be endogenous inhibitors of
la-hydroxylase activity, similar to phosphorus.
Guanidinosuccinic acid (GSA), a low molecular weight toxin
that is a putative uremic toxin, was also found to suppress
calcitriol production [36]. Infusion of a small quantity of GSA
(0.18 mg) to normal rats reduced the calcitriol production rate by
more than 40%. Although the levels of GSA were not measured
in these animals, the expected plasma concentrations was lower
than those of chronic moderate renal failure patients (0.35 0.03
mgldl; serum creatinine, 4 to 6 mg/dl [37] and hemodialysis
patients 2.3 1.4 mg/dl [38]). Thus, suppression of calcitriol
synthesis by GSA could occur in mild renal failure. Enzyme
kinetic analysis indicated that GSA inhibition was non-competi-
tive [36]. Preliminary experiments with cultured proximal tubule
cells also found that GSA (2 mg/dl) suppressed calcitriol produc-
tion by nearly 50%. On the other hand, other putative uremic
factors, such as spermine, spermidine, and methylguanine, had no
effect on calcitriol production [36].
It is generally accepted that calcitriol is produced by the kidney.
Recent studies, however, have provided evidence for extrarenal
production of calcitriol by macrophages in patients with renal
failure [39, 40]. We have studied the effect of GSA on calcitriol
production by normal human monocytes stimulated by several
growth factors [41]. In the absence of any growth factors, mono-
cytes made no detectable calcitriol. Interferon (1,000 U/mi),
tumor necrosis factor-a (500 U/mI), interleukin 1 (100 U/mi) and
interleukin 2 (250 U/mi) all stimulated calcitriol production. GSA
(2.0 mg/dl) partially inhibited the effects of the growth factors on
calcitriol production (Fig. 2). These results demonstrate that
cytokines are capable of stimulating calcitriol production by
normal human monocytes and that the production can be inhib-
ited by a putative uremic toxin.
Fig. 1. A. Renal ics-hydroxylase activity in rats
infused for 20 hours with 20 ml of uremic (D, N
= 4 rats) or normal (U, N = 4 rats) plasma
ultrafiltrate. N = 4 for each time period. Renal
la-hydroxylase activity was measured by the
generation of calcitriol 5, 10, 20, and 30
minutes after the addition of 25(OH)D3. B.
Renal la-hydroxylase activity of kidney
homogenate preincubated for 3 hours with5 10 20 30 uremic or normal plasma ultrafiltrate.
Reproduced with permission from reference
[32].
In summary, small molecular weight substances that accumu-
late in renal failure can suppress calcitriol production. Suppres-
sion of calcitriol production by uremic factors could occur in early
renal failure as calcitriol synthesis is inhibited by relatively small
quantities of uremic ultrafiltrate or GSA. Plasma levels of calcit-
riol in renal failure often fail to reflect the actual rate of synthesis,
as these uremic toxins also slow down metabolic degradation of
calcitriol [16].
Calcitriol receptor concentration in renal failure
Calcitriol-induced receptor synthesis is believed to be a tran-
scriptional event, although this issue remains controversial. Strom
et al have demonstrated that calcitriol increases the concentration
of receptor as well as receptor mRNA in vitamin D depleted rats
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Fig. 2. Guanidinosuccinic acid suppression of cytokine-induced calcitnol
production by peripheral human monocytes. Symbols are: (•) GF alone,(ri) GF + GSA; * P < 0.001. Preincubation with GSA (2 mg/dl) for 24
hours suppresses subsequent cytokine-induced calcitriol production. Ab-
breviations are: GSA, guanidinosuccinic acid; GF, growth factor; IFN,
interferon (1,000 U/mI); TNF-a, tumor necrosis factor a (500 U/mI); IL-i,
interleukin 1(100 U/mI), LL-2, interleukin 2 (250 U/mI). Reproduced with
permission from [41].
Growth factor
Hsu et a!: Calcitriol in renal failure 607
[421. However, others were unable to demonstrate association of
increased receptor concentration with transcription of receptor
mRNA [43, 44] or a consistent increase in receptor mRNA after
calcitriol treatment [45, 46]. In tissue culture systems, calcitriol
increased both receptor concentration and receptor mRNA levels
in ROS 17/2.8 cells and mouse 3T6 fibroblasts [47, 48]. On the
other hand, Brown et a! reported that calcitriol fails to up-regulate
calcitriol receptor in cultured bovine parathyroid cells [49].
Regulation of calcitriol receptor concentration is an important
mechanism for modulating cellular responsiveness to calcitriol
[50, 51], as the biological response to calcitriol is directly related
to receptor number [52] and occupancy [53]. Decreased calcitriol
receptor concentration could diminish the biological response to
calcitriol [54]. In chronic renal failure, the concentration of the
calcitriol receptor has been reported to be decreased [54—56]
although a recent study [57] reported no decrease in calcitriol
receptor in uremic rats. These investigators attributed the low
receptor concentrations reported in previous studies [54—56] to
proteolytic degradation of the receptor during preparation (with-
out addition of protease inhibitors). However, we have demon-
strated decreased intestinal calcitriol receptor concentration in
rats with chronic renal insufficiency [58] even when adequate
amounts of protease inhibitors were used throughout the prepar-
ative process. Further studies are needed to clarify this discrep-
ancy although we believe the preponderance of available evidence
suggests that the calcitriol receptor concentration is low in chronic
renal failure.
Assuming that the receptor concentration is truly decreased in
renal failure, three mechanisms have been suggested. (1) Because
calcitriol is known to up-regulate its own receptor [59], the low
plasma calcitriol concentration in renal failure could down-
regulate the calcitriol receptor. (2) The high plasma PTH concen-
tration in renal failure could decrease the concentration of
receptor. PTH down-regulates receptor and receptor mRNA in
ROS 17/2.7 cells. PTH also blocks calcitriol-induced up-regulation
of receptor in normal rats [48]. Furthermore, elevation of PTH
secondary to calcium deficiency is associated with a significant
down-regulation of kidney calcitriol receptor even in the presence
of a high concentration of plasma calcitriol [60]. (3) A previous
report has indicated that the concentration of receptor (Nmax) is
positively correlated with the glomerular filtration rate [54],
suggesting that accumulation of uremic toxins is responsible for
the lower concentration of calcitriol receptor in renal failure.
We tested the hypothesis that uremic toxins could be respon-
sible for the decreased receptor synthesis. Infusion of uremic
ultrafiltrate (30 ml for 20 hr) to normal rats reduced the receptor
concentration by 23% compared to rats infused with normal
ultrafiltrate. Calcitriol induced up-regulation of receptor was also
blocked by uremic ultrafiltrate, suggesting that uremic rats require
a higher dose of calcitriol in order to achieve receptor levels
similar to those of normal rats [58]. In summary, the combination
of low concentration of plasma calcitriol, high plasma PTH
concentration, and uremic toxins could explain decreased calcit-
rio! receptor concentrations in renal failure.
Hormone-receptor interaction with nuclear chromatin
The calcitriol receptor belongs to the steroid receptor super-
family which includes glucocorticoid, mineralcorticoid, androgen,
estrogen, progesterone, thyroid, and retinoic acid receptors.
These receptors have three major regions (I to III) of conserved
amino acids [61]. Region I includes the DNA binding domain and
contains 66 a highly conserved amino acid sequence. Region II
and III are located within the C-terminal or hormone binding
domain of the receptor. The DNA binding domain has two zinc
fingers which contain eight cysteine residues and two zinc mole-
cules. There are three variable and two conserved amino acid
residues situated at the end of the first finger. This region (P box)
serve to recognize specifically the primary nucleotide sequence of
the half sites [62]. Another region, located at the beginning of the
second finger (D box), contains five amino acid residues and is
critical for determining the half-site spacing [62]. A recent study
[63] has indicated that half-site spacing plays a critical role in
determining the hormonal response to steroids and retinoic acid.
For example, a direct repeat of AGGTCA separated by three,
four, or five nucleotides corresponds to the vitamin D, thyroid, or
retinoic acid receptor response elements, respectively [63]. The
similarity of the receptor DNA binding domain suggests that the
nuclear receptor genes of the steroid hormones evolved from
the same ancestor gene [64].
The DNA binding domain of nuclear receptors is sensitive to
sulfhydryl blocking agents. For example, p-chloromercuribenzo-
ate and iodoacetamide inhibit the binding of the calcitriol recep-
tor to DNA-cellulose [65] and pyridoxal 5'-phosphate inhibits the
binding of steroid hormone (glucocorticoid, estrogen, progester-
one, and androgen)-receptor complexes to DNA-cellulose [66—
69]. The latter compound reacts with r-amino group of lysine
residues in the DNA binding domain by forming a Schiff base and
thereby interfering with the receptor binding to DNA [66, 69]. An
interesting possibility is that uremic toxins could also diminish the
biological response to steroid hormones by chemical modification
of DNA binding domain.
The genomic action of calcitriol appears to be mediated
through a hormone-receptor complex interacting to regulate gene
expression in a manner analogous to other steroid hormones. The
hormone-receptor complex is thought to interact with specific
DNA sequences regulating the transcription rate of target genes.
The resultant mRNA species are then translated into proteins
which, after being processed, are ultimately responsible for the
biological activity of calcitriol [70—73]. A defect in receptor
function could lead to diminished biological activity of the hor-
mone. The consequences of a functional defect of the calcitriol
receptor is best illustrated by type II vitamin D dependent rickets,
a syndrome characterized by rickets, osteomalacia, hypocalcemia,
secondary hyperparathyroidism, and high plasma concentrations
of calcitriol. Genomic DNA analysis of affected family members
has identified a single nucleotide mutation in the DNA binding
domain encoding the receptor protein [74—78]. This mutation
produces a defective calcitriol receptor which is unable to interact
with DNA-cellulose in a normal fashion [76, 79]. Failure to
interact with vitamin D response elements diminishes the biolog-
ical action of calcitriol as reflected by decreased production of
bioactive proteins such as, 24-hydroxylase [801.
We asked whether calcitriol receptor function was altered in
renal failure. DNA-cellulose chromatography was used to model
the interaction of the calcitriol receptor with DNA. Normal
intestinal cytosolic receptor was incubated for three hours in
buffer solution containing tritiated calcitriol and a 20% solution of
either normal or uremic ultrafiltrate. Uremic ultrafiltrate signifi-
cantly reduced the hormone-receptor interaction with DNA-
cellulose [81]. The soluble hormone-receptor complex eluted as a
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single peak at 154 m ionic concentration with uremic ultrafiltrate
whereas the complex eluted at a discrete peak at 185 m ionic
concentration with normal ultrafiltrate (P < 0.001). Recently, we
found that one of the HPLC fractions of uremic ultrafiltrate
markedly inhibited the interaction of calcitriol receptor with
DNA-cellulose in proportion to the concentration of the uremic
fraction (Fig. 3) [58]. Receptors incubated with uremic ultrafil-
trate eluted as a single peak at a lower ionic strength than
receptors incubated with normal ultrafiltrate. Increasing the con-
centration of uremic ultrafiltrate (5 to 40%) progressively weak-
ened the interaction of the receptors with DNA-cellulose. In
contrast, the receptors incubated with an increasing concentration
of normal ultrafiltrate had stable binding properties except at a
concentration of 40% normal ultrafiltrate at which the receptor
had a slightly decreased interaction with DNA [58]. The in vitro
effect of uremic toxins to inhibit the interaction of receptor with
nuclear chromatin could block the biological action of calcitriol.
The DNA-cellulose binding characteristics of intestinal recep-
tors isolated from rats with chronic renal failure also differ from
those of receptor isolated from normal animals (Fig. 4) [58].
Receptors from normal rats eluted as a single peak at 0.22 M KCI
on a linear salt gradient whereas receptors from chronic renal
failure rats eluted as two distinct peaks, one of normal activity at
0.22 M KC1 and the other of weak activity at 0.12 M KC1. Infusion
Fig. 3. Elution profile of 3H-calcitriol-labeled
intestinal receptor from DNA-cellulose by KC1.
Symbols are: (D) 5%; (•) 10%; (D) 20%; (K')
30%; () 40%. The receptors were
preincubated for 3 hours with various
concentrations of HPLC fraction 4 of normal or
uremic ultrafiltrates. Receptors incubated with
uremic ultrafiltrate (B) eluted as single peaks at
186 mM (5%), 178 mM (10%), 155 mi (20%),
131 mt.i (30%), and 114 mM (40%),
respectively, while receptors incubated with
normal ultrafiltrate (A) eluted as single peaks at
194 mtvi (5%), 194 mM (10%), 194 m (20%),
194 mtvi (30%), and 186 mi (40%),
respectively. C. Summaiy of (A and B)
receptors incubated with 0 to 40% ultrafiltrates
eluted at various concentration of KC1. Symbols
are: (El) normal; (•) uremic. Reproduced with
permission from reference [58].
Fig. 4. Elution profile of 3H-calcitriol.labeled
intestinal receptor from DNA-cellulose by KCI.
The receptor of a subtotally nephrectomized rat
eluted as two single peaks, one at 227 mii KC1,
the other at 123 mrvi KC1, whereas the receptor
of sham control eluted as a single peak at 228
mM KCI. Reproduced with permission from
reference [58].
of uremic ultrafiltrate to normal rats for 20 hours resulted in
identical receptor binding characteristics to those of rats with
renal failure, suggesting that uremic toxins produce the abnormal
binding properties of the receptor [58]. A recent study has
suggested that proteolysis of calcitriol receptor during preparation
could occur in uremic animals if protease inhibitors are not added
in the tissue [57]. It is possible that the receptor eluted at 0.12 M
KCI could be a proteolytic fragment artificially produced by the
action of an endogenous protease during receptor preparation in
uremic animals (protease inhibitors were added in the prepara-
tion). The protease preferentially cleaves the DNA binding site,
resulting in a receptor with an altered binding property [82, 83].
Although the receptors from normal and renal failure rats had
identical sucrose gradient sedimentation coefficients of 3.3 S, this
analysis may not distinguish between receptors with small differ-
ences in molecular weight [58]. It should be noted, however, that
the hormone-receptor complex prepared from rats with acute
renal failure (5 hr of bilateral ureteral obstruction) eluted as a
single peak at 0.22 M KCI even though these animals were nearly
as uremic as nephrectomized renal failure rats [58]. The normal
binding property of the receptor obtained from rats with acute
renal failure suggests that: (1) generation of two binding receptors
occurs after five hours of renal failure, and (2) proteolytic
degradation of receptor, if occurs during preparation, is not due
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to uremia. The latter is further supported by the fact that the
animals infused with uremic ultrafiltrate had two kinds of recep-
tors even though the blood creatinine and urea nitrogen concen-
trations were not different from rats infused with normal plasma
ultrafiltrate [15]. These observations cast doubt on the possibility
of enhanced proteolytic degradation of receptor in the uremic
state.
There appears to be a qualitative difference in the DNA binding
properties between receptors incubated with uremic ultrafiltrate
and receptors obtained from chronic renal failure rats. Receptors
incubated with uremic ultrafiltrate behave as a homogeneous pool
of proteins with gradually weakened DNA binding at higher
concentrations of uremic ultrafiltrate. Receptors isolated from
renal failure rats appear to exist as two distinct populations; one
population binds DNA normally and the other binds DNA
weakly. The receptors isolated from renal failure rats apparently
are a mixture of normal and greatly impaired receptors. As stated
previously, receptors with abnormal binding affinity developed
several hours after uremia, suggesting the effect of uremia on
receptor modification is slower in viva Since half-life of normal
receptor is estimated to be four hours [84], therefore, receptors
isolated from chronic renal failure rats consisted of normal (newly
synthesized) and abnormal (chemically modified, older) receptor.
It is important to point out that a substantial literature exists on
DNA cellulose binding to members of steroid receptor superfam-
ily [74, 76, 79, 85]. These studies demonstrate that DNA-cellulose
binding characteristics accurately predict the action of receptors
on their specific response elements. Thus, it is highly probable
that uremic ultrafiltrate also will impair the interaction between
calcitriol receptor and its specific response elements. Our prelim-
inary experiments confirm that HPLC fractionated uremic ultra-
filtrate indeed inhibited the calcitriol receptor binding to osteo-
calcin gene (provided by Dr. H. F. DeLuca, Professor of
Biochemistry, Department of Biochemistry, College of Agricul-
ture and Life Sciences, University of Wisconsin-Madison, Wiscon-
sin, USA). The inhibition appeared to be dose-dependent using
uremic ultrafiltrate concentrations of 30, 60, and 100%. By
contrast, normal ultrafiltrate did not inhibit receptor binding to
osteocalcin gene even at an ultrafiltrate concentration of 100%.
Further, binding of osteocalcin gene by receptors isolated from
chronic renal failure was also decreased (unpublished observa-
tion). It should be noted that these observations were made in
vitro; the relevance of these interactions in vivo remains to be
determined.
Using reconstituted intestinal nuclei [86, 87], we have studied
the effect of HPLC fractionated uremic plasma ultrafiltrate on in
vitro nuclear uptake of calcitriol-receptor complex [88]. Nuclear
uptake of the labeled calcitriol receptor was significantly de-
creased within 15 minutes of incubation with uremic ultrafiltrate.
The nuclear uptake of labeled calcitriol receptor obtained from
rats with renal failure or from rats infused with uremic ultrafiltrate
was also significantly lower than that from normal rats or from rats
infused with normal ultrafiltrate, respectively. The impaired nu-
clear uptake of calcitriol receptor may be a consequence of
decreased DNA binding. While the magnitude of the effect
observed in this reconstituted nuclei model is quite modest, it is
possible that diminished nuclear uptake of the calcitriol receptor
complex in the intact cell accounts for part of the calcitriol
resistance seen in renal failure.
There are several possible explanations for the observed
changes in receptor binding properties. Functional activation of
receptor requires calcitriol-induced phosphorylation [89, 90]. Ure-
mic toxins could reduce calcitriol binding to the receptor and
inhibit receptor phosphorylation. This mechanism is unlikely as
we have found that uremic ultrafiltrate did not reduce hormonal
binding to the receptor [88]. Alternatively, the uremic toxins could
directly inhibit phosphorylation at the DNA binding domain and
hinder a conformational change of the receptor. Recent studies
have suggested that the interaction of receptor with a specific
vitamin D response element requires a mammalian cell nuclear
accessory factor [72, 91]. The formation of a heterodimer made of
receptor with nuclear accessory factor is critical for high affinity
DNA binding. In the absence of this nuclear factor, receptor
interacts weakly with the vitamin D responsive element [72, 92].
Thus, decreased synthesis of this nuclear accessory factor in
chronic renal failure (not yet demonstrated) could reduce calcit-
riol receptor interaction with DNA.
Biological action of calcitriol in renal failure
The induction of 24-hydroxylase activity by calcitriol is believed
to be a classical, receptor-mediated, steroid hormone action [80,
93, 94]. Production of 24-hydroxylase is one of the major biolog-
ical actions of calcitriol. It appears that stimulation of this enzyme
by calcitriol in target cells will result in self-induced metabolism of
calcitriol to inactive metabolites. This pathway plays an important
role in the feedback modulation of the biological activity of
calcitriol; 24-hydroxylase increases calcitriol degradation and
therefore limits receptor up-regulation and cellular responsive-
ness to calcitriol [53].
In type II vitamin D dependent rickets, abnormal DNA-
cellulose binding of receptor is associated with end-organ resis-
tance to calcitriol in vivo and decreased production of calcitriol-
induced 24-hydroxylase by skin fibroblasts of the patients [79, 80].
Therefore, we studied the effects of several compounds that
interfere with the interaction between receptor and DNA-cellu-
lose on 24-hydroxylase activity in vivo. Pyridoxal 5'-phosphate
inhibits the binding of the calcitriol receptor to DNA-cellulose
[95]. When pyridoxal 5'-phosphate was infused for 20 hours (4
mg/100 g) to normal rats, calcitriol-induced 24-hydroxylase activ-
ity was suppressed [95]. Uric acid and theophylline also interfere
with the receptor binding to DNA-cellulose [34]. Infusion of
sodium urate and theophylline to normal rats also suppressed
metabolic clearance of calcitriol, presumably through suppression
of 24-hydroxylase activity [34]. Finally, uremic ultrafiltrate, which
inhibits the hormone receptor interaction with DNA-cellulose,
decreased 24-hydroxylase activity when normal rats were infused
for 20 hours [81]. The up-regulation of 24-hydroxylase activity by
calcitriol was also inhibited by uremic ultrafiltrate [811. Taken
together, these studies provide evidence that chemical substances
which inhibit hormone-receptor complex interaction with DNA-
cellulose in vitro could diminish biological response to calcitriol in
vivo.
Conclusions
Calcitriol metabolism and activity are markedly and progres-
sively affected by renal failure. These perturbations contribute to
abnormal bone and mineral metabolism that are characteristic of
chronic renal failure. Recent studies indicate renal failure inter-
feres with calcitriol synthesis, receptor interaction with DNA,
nuclear uptake of the calcitriol-receptor complex, and receptor
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synthesis. In the aggregate, these abnormalities appear to impede
the biological actions of calcitriol in renal failure. While several
factors may underlie each of these perturbations, we have recently
found that specific, but heretofore unidentified, uremic toxins
could produce many of the described alterations of calcitriol
metabolism and action. We predict that the toxic effects of uremia
are not limited to the calcitriol receptor. Other receptors in the
steroid superfamily may be adversely affected by uremia via the
same mechanisms, especially retinoic acid and thyroid receptors,
which have many similarities to the calcitriol receptor. These
findings have significant implications for understanding the met-
abolic consequences of uremia.
CHEN H. Hsu, SANJEEVKUMAR R, PATEL, ERIC W. YOUNG,
and RAYMOND VANHOLDER
Ann Arbor, Michigan, USA and Ghent, Belgium
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